|
Inzucchi S E, Bergenstal R M, Buse J B. Management of hyperglycemia in type 2 diabetes:a patient-centered ap-proach position statement of the American Diabetes Associa-tion (ADA)and the European Association for the Study of Diabetes (EASD) [J]. DIABETES CARE, 2012(6):1364.
|
|
Del Prato S, Barnett A H, Huisman H. Effect of linagliptin monotherapy on glycaemic control and markers ofβ-cellfunction in patients with inadequately control ed type 2 diabetes:a randomized control ed trial [J]. Diabetes Obesity and Metabolism, 2011(3):258.
|
|
Meier J J, Bonadonna R C. Role of reducedβ-cellmass ver-sus impairedβ-cellfunction in the pathogenesis of type 2 di-abetes [J]. DIABETES CARE, 2013, (Supplement 2):S113.
|
|
Donath M Y, Shoelson S E. Type 2 diabetes as an inflamma-tory disease [J]. Nature reviews Immunology, 2011(2):98.
|
|
陈影, 吕玲, 付丽莉. 诺和灵30R和诺和锐30治疗2型糖尿病肾病维持性血液透析患者的疗效观察 [J]. 哈尔滨医药, 2013(3):189.
|
|
王安宁, 叶小英, 王峰. 诺和锐30 与诺和灵30R治疗初诊重症2型糖尿病疗效比较 [J]. 中国实用医药, 2012, (28):151.
|
|
Liebl A, Prusty V, Valensi P. Ten years of experience with biphasic insulin aspart 30 [J]. DRUGS, 2012, (11):1495.
|
|
Skriver M V, Stovring H, Kristensen J K. Short-term impact of HbA1 c on morbidity and al-cause mortality in people with type 2 diabetes:a Danish population-based observational study [J]. DIABETOLOGIA, 2012(9):2361.
|
|
崔影, 邢桂红, 屈丹. 诺和锐30与诺和灵30R治疗初诊2型糖尿病疗效对比 [J]. 中国医药导刊, 2011(2):278.doi: 10.3969/j.issn.1009-0959.2011.02.057.
|
|
林桂娥, 张圳锋, 邱伟忠. 诺和灵30R及诺和锐30治疗2型糖尿病疗效差异分析 [J]. 齐齐哈尔医学院学报, 2014(7):986.
|
|
钟绍, 方玲娜, 潘颖. 诺和锐30和诺和灵30R治疗2型糖尿病疗效比较 [J]. 中国血液流变学杂志, 2011(3):434.doi: 10.3969/j.issn.1009-881X.2011.03.018.
|
下载:
苏公网安备 32100302010246号